Meeting
2013 ASCO Annual Meeting
Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.
Authors
Sten Nilsson
Karolinska University Hospital, Stockholm, Sweden
Sten Nilsson , A. Oliver Sartor , Oyvind S. Bruland , Fang Fang , Anne-Kirsti Aksnes , Chris Parker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00699751
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5038)
DOI
10.1200/jco.2013.31.15_suppl.5038
Abstract #
5038
Poster Bd #
35E
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.
First Author: Sten Nilsson
Poster
2018 Genitourinary Cancers Symposium
Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).
First Author: Bertrand F. Tombal
Poster
2013 Genitourinary Cancers Symposium
Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA).
First Author: Nicholas J. Vogelzang
Poster
2016 ASCO Annual Meeting
Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM) – A multicenter analysis.
First Author: Aurelius Gabriel Omlin